Journal List > J Korean Ophthalmol Soc > v.52(6) > 1009055

Lee, Choi, Cheong, Jung, Jin, Park, and Lee: Effects of Mitomycin C on Scleral Collagen Fibrils According to Atomic Force Microscopy

Abstract

Purpose

To investigate the effects of mitomycin C on the scleral collagen surfaces using atomic force microscopy (AFM).

Methods

Two non-contact mode AFM machines were used to observe changes in the morphological characteristics of human scleral surfaces before and after one, three, and five minutes of 0.02% mitomycin C application. Based on AFM topography and deflection images of the collagen fibril, the morphological characteristics of scleral fibrils including the fibril diameter and D-period were measured using the line profile.

Results

The sclera collagen fibril treated with 0.02% mitomycin C for one minute did not show any significant increases in mean fibril diameter (155.04 ± 17.46 nm) or mean D-periodicity (70.02 ± 3.33 nm), compared to those of the control group. However, the scleral collagen fibrils treated with 0.02% mitomycin C for three and five minutes showed significant increases in mean fibril diameter (182.33 ± 16.33 nm, 199.20 ± 12.40 nm, respectively) and mean D-periodicity (70.27 ± 13.66 nm, 72.75 ± 19.32 nm, respectively), compared to those of the control group.

Conclusions

The present study examined the structural changes in the scleral collagen fibrils before and after mitomycin C application according to atomic force microscopy. The results indirectly suggest that three or more minutes of 0.02% mitomycin C application affects the morphology of scleral collagen.

References

1. Danshiitsoodol N, de Pinho CA, Matoba Y, et al. The mitomycin C (MMC)-binding protein from MMC-producing microorganisms protects from the lethal effect of bleomycin: crystallographic analysis to elucidate the binding mode of the antibiotic to the protein. J Mol Biol. 2006; 360:398–408.
crossref
2. Mao Y, Varoglu M, Sherman DH. Molecular characterization and analysis of the biosynthetic gene cluster for the antitumor antibiotic mitomycin C from Streptomyces lavendulae NRRL 2564. Chem Biol. 1999; 6:251–63.
crossref
3. Oum BS, Lee JS. The effect of Mitomycin C (MMC) on inhibition of cellular proliferation and type_I collagen, laminin synthesis of pterygial mesenchymal cell. J Korean Ophthalmol Soc. 1999; 40:712–20.
4. Willems EW, Nooter K, Verweij J. Antitumor antibiotics. Chabner BA, Longo DL, editors. Cancer Chemotherapy & Biotherapy: Principles and Practice. 4th ed.Philadelphia: Lippincott Williams & Wilkins;2006. 1:chap. 16.
5. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-in-fusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002; 20:1996–2004.
crossref
6. Lee TS, Rhee K. The effect of Mitomycin C eyedrops on prevention of intermal ostium obstruction after endonasal dacryocystorhinostomy. J Korean Ophthalmol Soc. 1998; 39:1915–20.
7. Park DJ, Kwak MS. The effect of Mitomycin C on the success rate of endoscopic dacryo cystorhinostomy. J Korean Ophthalmol Soc. 2000; 41:1674–9.
8. Anderson RL, Edwards JJ. Indications, complications and results with silicone stents. Ophthalmology. 1979; 86:1474–87.
crossref
9. Tarr KH, Constable IJ. Late complications of pterygium treatment. Br J Ophthalmol. 1980; 64:496–505.
crossref
10. Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology. 1992; 99:1647–54.
crossref
11. Wan Norliza WM, Raihan IS, Azwa JA, Ibrahim M. Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy. Cont Lens Anterior Eye. 2006; 29:165–7.
crossref
12. Song HY, Im JS, Kwak JY. Acellular dermal allograft transplantation in patients with scleromalacia after pterygium excision. J Korean Ophthalmol Soc. 2008; 49:1685–9.
crossref
13. Na YS, Joo MJ, Kim JH. Results of scleral allografting on scleral necrosis following pterygium excision. J Korean Ophthalmol Soc. 2005; 46:402–9.
14. Anduze AL, Burnett JM. Indications for and complications of mi-tomycin-C in pterygium surgery. Ophthalmic Surg Lasers. 1996; 27:667–73.
crossref
15. Keeley FW, Morin JD, Vesely S. Characterization of collagen from normal human sclera. Exp Eye Res. 1984; 39:533–42.
crossref
16. Spitznas M, Luciano L, Reale E. Fine structure of rabbit scleral collagen. Am J Ophthalmol. 1970; 69:414–8.
crossref
17. Spitznas M. The fine structure of human scleral collagen. Am J Ophthalmol. 1971; 71:68.
crossref
18. Komai Y, Ushiki T. The three-dimensional organization of collagen fibrils in the human cornea and sclera. Invest Ophthalmol Vis Sci. 1991; 32:2244–58.
19. Marshall GE, Konstas AG, Lee WR. Collagens in the aged human macular sclera. Curr Eye Res. 1993; 12:143–53.
crossref
20. Lin Z, Chen X, Ge J, et al. Effects of direct intravitreal dopamine injection on sclera and retina in form-deprived myopic rabbits. J Ocul Pharmacol Ther. 2008; 24:543–50.
crossref
21. Meek KM, Fullwood NJ. Corneal and scleral collagens–a micro-scopist's perspective. Micron. 2001; 32:261–72.
crossref
22. Fullwood NJ, Hammiche A, Pollock HM, et al. Atomic force microscopy of the cornea and sclera. Curr Eye Res. 1995; 14:529–35.
crossref
23. Meller D, Peters K, Meller K. Human cornea and sclera studied by atomic force microscopy. Cell Tissue Res. 1997; 288:111–8.
crossref
24. Yamamoto S, Hitomi J, Sawaguchi S, et al. Observation of human corneal and scleral collagen fibrils by atomic force microscopy. Jpn J Ophthalmol. 2002; 46:496–501.
crossref
25. Kadler KE, Holmes DF, Trotter JA, Chapman JA. Collagen fibril formation. Biochem J. 1996; 316:1–11.
crossref
26. Kwak JJ, Lee DH, Lew HM. Endoscopic dacryocystorhinostomy with Mitomycin-C application. J Korean Ophthalmol Soc. 1998; 39:2211–7.
27. Lee KS, Byun YJ. Dacryocystorhinostomy with intraoperative Mitomycin C. J Korean Ophthalmol Soc. 1998; 39:1909–14.
28. Kim JH, Lee HB, Yoon DK. Scleral grafts fer the cases of scleral perforation, scleral ectasia and scleral necrosis. J Korean Ophthalmol Soc. 1978; 19:55–64.
29. Manning CA, Kloess PM, Diaz MD, Yee RW. Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. Ophthalmology. 1997; 104:844–8.
30. Khaw PT, Sherwood MB, Doyle JW, et al. Intraoperative and post operative treatment with 5-fluorouracil and mitomycin-c: long term effects in vivo on subconjunctival and scleral fibroblasts. Int Ophthalmol. 1992; 16:381–5.
crossref
31. Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology. 1992; 99:1647–54.
crossref
32. Wan Norliza WM, Raihan IS, Azwa JA, Ibrahim M. Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy. Cont Lens Anterior Eye. 2006; 29:165–7.
crossref
33. Solomon A, Kaiserman I, Raiskup FD, et al. Long-term effects of mitomycin C in pterygium surgery on scleral thickness and the conjunctival epithelium. Ophthalmology. 2004; 111:1522–7.
crossref

Figure 1.
(A) Atomic force microscopy (AFM) block diagram, and (B) force vs. distance and relative zone modes.
jkos-52-671f1.tif
Figure 2.
Representative atomic force microscopy topography images of the dehydrated human sclera in various scan sizes such as (A) 20 × 20 µm2, (B) 5 × 5 µm2, and (C) 1 × 1 µm2.
jkos-52-671f2.tif
Figure 3.
Representative three-dimensional images of the dehydrated human sclera in various scan sizes such as (A) 20 × 20 µm2, (B) 5 × 5 µm2, and (C) 1 × 1 µm2.
jkos-52-671f3.tif
Figure 4.
Representative examples of the diameter (C) and D-banding (D) measurements using line profiling plots on AFM topography (A) and deflection images (B) of the dehydrated scleral collagen fibrils in a scan size of 5 × 5 μ m2.
jkos-52-671f4.tif
Figure 5.
Representative AFM topography (A), deflection (B), and three-dimensional images (C) of the dehydrated scleral collagen fibrils in a scan size of 5 × 5 μ m2.
jkos-52-671f5.tif
Figure 6.
Representative AFM topography (A), deflection (B), and three-dimensional images (C) of the dehydrated scleral collagen fibrils with 0.02% mitomycin C application for 5 minutes in a scan size of 5 × 5 μ m2.
jkos-52-671f6.tif
Table 1.
Morphological changes in the sclera fibrils for control and MMC-treated groups
Parameter Control MMC 1 min MMC 3 min MMC 5 min
Diameter (mean ± SD, nm) 145.22 ± 17.78 155.04 ± 17.46 182.33 ± 16.33* 199.20 ± 12.40
D-banding (mean ± SD, nm) 69.14 ± 14.15 70.02 ± 3.33 70.27 ± 13.66 72.75 ± 19.32

MMC = Mitomycin C.

* p-value < 0.005 vs. Control group

p-value < 0.0001 vs. Control group.

TOOLS
Similar articles